This filing provides a preview of Pfizer's upcoming Q2 earnings report, highlighting analyst consensus estimates for lower EPS and revenue year-over-year. Several analysts have recently cut their price targets for PFE, indicating a cautious outlook despite positive Phase 3 trial results for LITFULO.
The filing details analyst expectations for Pfizer's Q2 earnings, projecting a decrease in both EPS and revenue compared to the prior year. This suggests a challenging quarter for the company, which is reflected in the recent trend of analysts lowering their price targets. While positive Phase 3 results for LITFULO offer a long-term opportunity, the immediate outlook for Q2 appears subdued. Traders should be aware of the potential for short-term volatility around the earnings release, especially if actual results deviate significantly from these lowered expectations. The consistent downward revisions in price targets across multiple firms indicate a broader cautious sentiment among analysts.